The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
The management of type 2 diabetes has become increasingly controversial. Tight control has been advocated for years; however, there was a recent revision published by the American College of Physicians in which limitations were made to liberalize glycaemic goals for most diabetics, targeting a level between 7% and 8%. In recent years, the evolution of diabetes care has been such that more potent drugs, with low risk of hypoglycaemia when used in the absence of insulin or secretagogues, have made their way into the market place. Use of such agents has made it easier to achieve greater glycaemic control reasonably safely. Unfortunately, it appears that there has been a significant amount of inertia over the past decade, which continues to persist. Relaxing the glycaemic control targets, as recommended by the American College of Physicians, may only help to propagate this inertia.
['Morales|Javier|J|0000-0003-1005-0311', 'Assumpcao-Morales|Merces|M|']
D048909:Diabetes Complications D003924:Diabetes Mellitus, Type 2 D016903:Drug Monitoring D004359:Drug Therapy, Combination D006442:Glycated Hemoglobin A D006801:Humans D006943:Hyperglycemia D007003:Hypoglycemia D007004:Hypoglycemic Agents D007328:Insulin D017410:Practice Guidelines as Topic D010818:Practice Patterns, Physicians' D057285:Precision Medicine D014481:United States
type 2 diabetes Canagliflozin antidiabetic drug basal insulin beta cell function diabetes complications